Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2016, Article ID 3484673, 17 pages
http://dx.doi.org/10.1155/2016/3484673
Research Article

Axitinib Has Antiangiogenic and Antitumorigenic Activity in Myxoid Liposarcoma

1Centre for Cancer Research, Hudson Institute for Medical Research, 27-31 Wright Street, Clayton, VIC 3168, Australia
2The Ritchie Centre, Hudson Institute for Medical Research, 27-31 Wright St, Clayton, VIC 3168, Australia
3Monash University, Wellington Road, Clayton, VIC 3168, Australia

Received 14 April 2016; Revised 8 August 2016; Accepted 20 September 2016

Academic Editor: R. Lor Randall

Copyright © 2016 Lauren T. Kerr et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

The Supplementary Material files contains the following: Supplementary Methods. Supplementary Table 1: Drug IC50 tabulation. Supplementary Table 2: Drug combination tabulation. Supplementary Figure S1: Drug dilution series to determine IC50: MLS 402 and MLS 1765. Supplementary Figure S2: Axitinib and salinomycin combination trials. Supplementary Figure S3: Axitinib and 4EGI-1 combination trials. Supplementary Figure S4: Salinomycin and 4EGI-1 combination trials. Supplementary Figure S5: Salinomycin and ABT-737 combination trials. Supplementary Figure S6: Trial of combinations of salinomycin/dasatinib and salinomycin/doxorubicin against MLS 1765. Supplementary Figure S7: Trial of combinations of ABT-737/4EGI-1 and ABT-737/axitinib against MLS 1765. Supplementary Figure S8: Trial of combinations of doxorubicin/4EGI-1 and doxorubicin/axitinib against MLS 1765. Supplementary Figure S9: Molecular characterization of MLS 402 cells. Supplementary Figure S10: Hematoxylin and eosin microphotographs of MLS 1765 xenograft tissue. Supplementary Figure S11: Drug dilution series to determine IC50: SW 872.

  1. Supplementary Material
  2. Supplementary Material